HK$2.65HK$0.00 (0.0%)
Jilin Province Huinan Changlong Bio-pharmacy Company Limited’s quoted price sits in the upper half of its reported 52-week range, 11.67% below the high.
Loading market information…
HKSE · 2251.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 06:51 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Beijing Airdoc Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 44.63% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Beijing Airdoc Technology Co., Ltd.’s next earnings report is currently expected on Apr 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Beijing Airdoc Technology Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Beijing Airdoc Technology Co., Ltd. provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally. The company offers a software as a medical device (SaMD) product, Airdoc-AIFUNDUS, which is an AI-assisted diagnosis of retinal detection product that is available in three versions comprising version 1.0 for the diagnosis of diabetic retinopathy, version 2.0 that address various fundus diseases, and version 3.0 for the diagnosis of pathological myopia and retinal detachment. It also provides the AI-FUNDUSCAMERA-P, a portable automatic and self-service fundus camera that can complete the retinal image capture without an operator; AI-FUNDUSCAMERA-D, a fully automatic and self-service desktop fundus camera; and AI-FUNDUSCAMERA-M, a multimodal health scanner that integrates biosensors that supports a number of health detection functions. In addition, the company offers health risk assessment solutions to detect risk indicators, such as retinal abnormalities and vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease, and anemia. In addition, it develops SaMD products for glaucoma and cataracts detection; an AI-driven integrated myopia intervention solutions, including the PBM LED myopia therapy device; and an AI-based visual training product for the treatment of strabismus and amblyopia. The company was formerly known as Beijing Tulip Partner Technology Co., Ltd. and changed its name to Beijing Airdoc Technology Co., Ltd. in December 2020. Beijing Airdoc Technology Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, the People’s Republic of China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2022 | Mar 23, 2023 | -HK$0.87 | HK$86.03M-63.8% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$2.65HK$0.00 (0.0%)
Jilin Province Huinan Changlong Bio-pharmacy Company Limited’s quoted price sits in the upper half of its reported 52-week range, 11.67% below the high.
HK$6.40HK$0.00 (0.0%)
Sunho Biologics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.95% below the high.
HK$0.89HK$0.00 (0.0%)
Kindstar Globalgene Technology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.56% below the high.
HK$0.98HK$0.00 (0.0%)
Brii Biosciences Limited’s quoted price sits in the lower half of its reported 52-week range, 48.42% below the high.
HK$3.80HK$0.00 (0.0%)
Wuhan YZY Biopharma Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 54.76% below the high.
HK$2.52HK$0.00 (0.0%)
3D Medicines Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.83% below the high.
HK$0.98HK$0.00 (0.0%)
Venus Medtech (Hangzhou) Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.61% below the high.
HK$0.58HK$0.00 (0.0%)
Broncus Holding Corporation’s quoted price sits in the lower half of its reported 52-week range, 78.91% below the high.
